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Porous biphasic calcium phosphates (BCP) were fabricated using reverse thermo-
responsive hydrogels with hydroxyapatite (HAp) and β-tricalcium (β-TCP) powder and
planetary centrifugal mixer. This hydrogel mixture slurry will shrink and compress the
HAp powder during the sintering process. The porous bioceramics are expected to have
good mechanical properties after sintering at 1200 1C. Reverse thermo-responsive hydro-
gels of poly[(N-isopropylacrylamide)-co-(methacrylic acid)] p(NiPAAm–MAA) were synthe-
sized by free-radical cross-linking copolymerization, and their chemical properties were
evaluated by nuclear magnetic resonance spectroscopy, infrared spectroscopy, and
electrospray-ionization mass spectrometry. The lower critical solution temperature (LCST)
of the hydrogel was determined using turbidity measurements. A thermogravimetric
analysis was used to examine the thermal properties. The porous bioceramic properties
were analyzed by X-ray diffraction, scanning electron microscopy, bulk density, compres-
sive strength testing and cytotoxicity. The compressive strength and average porosity of
the porous bioceramics were examined at approximately 6.8 MPa and 66% under 10 wt%
p(NiPAAm–MAA)¼99:1 condition. The ratio of HAp/β-TCP can adjust two different com-
positional behaviors during the 1200 1C sintering process without resulting in cell toxicity.
The (rhBMP-2)-HAp-PLGA carriers were fabricated as in our previous study of the doubleElsevier Ltd.
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micrographs of the 1-mm defect in the femurs, with the rhBMP-2 carrier group, the
bioceramic spacer group and the bioceramic spacer with rhBMP-2 carriers group showing
better callus formation around the femur defect site than the control group. The optimal
dual effects of the bone growth factors from osteoconductive bioceramics and osteoinduc-
tive rhBMP-2 carriers produced better bone formation.
& 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Commonly, salvage procedures for bone cancer, comminuted
open fractures, and severe atrophic non-unions often cause
large bone defects. Because of the lack of an osteoconductive
matrix for bone regeneration, these procedures require
further surgical treatment. The typical gold-standard treat-
ment is autogenous bone grafts, which require harvesting
‘donor’ bone from a non-weight-bearing site of the same
patient for transplantation into the defect site (Bauer and
Muschler, 2000). However, the use of this technique is
severely restrained due to limited quantities and the con-
siderable donor site morbidity associated with the harvest
(Silber et al., 2003; Lord et al., 1988). Other common sources of
bone graft replacements are allografts and xenogeneic bone
grafts. However, the disadvantages of allografts and xeno-
geneic bone grafts are the immune- and disease-related
complications (Lord et al., 1988; Muscolo et al., 2006). Many
bone substitute materials that were intended to replace the
need for autologous or allograft tissue have been evaluated
over the last two decades (Hench and Polak, 2002; Kretlow
and Mikos, 2007). The current bone formation strategy is that
artiﬁcially synthesized biomaterials should simultaneously
have both osteoinductive and osteoconductive functions,
allowing for integration into the surrounding host bone
(Stevens, 2008). Depending on the relevant tissue engineering
criterion, the ideal basic hypothesis is that the implanted
materials will be resorbed and replaced over time by the
body's own newly regenerated bone tissue (Langer and
Vacanti, 1993). Some studies reported that porous biphasic
bioceramics of hydroxyapatite/β-tricalcium phosphate (HAp/
β-TCP) can promote osteoconduction during new bone for-
mation in in vivo experiments (Daculsi et al., 2003; Yamada
et al., 1997). Furthermore, the resorption rate of this porous
bioceramic can be tailored using the HAp/β-TCP ratio so that
the bioceramic persists for years following implantation,
while other calcium phosphates have a greater capacity to
be resorbed (Yamada et al., 1997).
Hulbert et al. indicated that optimal bone tissue ingrowth
was found for pore sizes greater than 100 μm due to cell sizes
(Daculsi et al., 2003). For migration and transport, the optimal
pore size for porous bone substitutes has been explored by
many investigators (Hulbert et al., 1970; Stevens, 2008; Uchida
et al., 1985). According to the current literature, the optimal
pore size is estimated to be 100–600 μm (Hulbert et al., 1970;
Uchida et al., 1985). However, the brittle nature of porous
bioceramic substitutes cannot match the toughness of bone,
which limits the use of these materials for clinical load-
bearing applications (Fan et al., 2012). Therefore, the currentchallenges for the tissue engineering of porous bioceramics
are to match both the mechanical and biological context of
the real bone tissue matrix and to support the ingrowth of
neovascularization and cells (Stevens, 2008). Several technol-
ogies exist for manufacturing strong and reliable porous
ceramics. These scaffold preparation methods allow one to
control the pore sizes and yield scaffolds with interconnected
pores and the desired geometry; however, the mechanical
strength is often too low to match the compressive strength
of cancellous bone (approximately 4–12 MPa) (Gauthier et al.,
1999; Huglin et al., 1997; Ramay and Zhang, 2003). Increasing
the compressive strength of scaffolds without decreasing the
porosity and pore size is a challenge for researchers.
The potential of reverse thermo-responsive hydrogels has
been recognized for tissue regeneration because gelation can
occur as the temperature increases above the lower critical
solution temperature (LCST), which is constructed to be
below body temperature (Cui et al., 2007; Gan et al., 2009;
Rezwan et al., 2006). The pNiPAAm (poly(N-isopropylacryla-
mide)) can exhibit gel volume contraction if the temperature
increases above the LCST of 32 1C (Fujishige et al., 1989;
Heskins and Guillet, 1968). At 32 1C, the induced phase
transition of pNiPAAm in aqueous solution may mainly be
driven by the thermal destruction of hydrogen bonds
between water molecules and hydrophilic groups, such as –
CO- and –NH- in the NiPAAm monomer. Furthermore, the
interaction between hydrophobic segments on the polymer
increases with increased temperature (Hirotsu, 1987; Otake
et al., 1990; Solis et al., 2005). Of pNiPAAm-based copolymers,
the copolymer poly(N-isopropylacrylamide-co-methacrylic
acid) (p(NiPAAm–MAA)) is of special interest because the
methacrylic acid (MAA) group introduces additional ionized
groups to the copolymer. As a result, the copolymer contains
hydrophobic segments and hydrophilic groups and can be
useful for the absorbance of metal ions (Tian et al., 2008).
Therefore, p(NiPAAm–MAA) hydrogels should be beneﬁcial
for the dispersion of hydrophilic and hydrophobic powders.
However, a challenge with using pNiPAAm in biomedical
applications, such as controlled drug delivery or tissue
engineering scaffolds, is that pNiPAAm is not biodegradable,
which limits its use in temporary implantation applications.
Considering the above ﬁndings, we aimed to fabricate a
new scaffold possessing both an even distribution of poros-
ities for cell ingrowth and optimal compressive strength. We
hypothesize that the p(NiPAAm–MAA) hydrogel would shrink
and compress the HAp powder during sintering as the
temperature increases. The porous bioceramics formed using
this material would have mechanical properties similar to
those of cancellous bone. We also tested the cell cytotoxicity
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applications. Then, we evaluated the new porous bioceramic
in vivo and combined our results with those of our previous
controlled release of rhBMP-2 microsphere carriers (Wang
et al., 2009) to determine that these materials can be used as
both osteoconductive and osteoinductive functional bone
scaffolds in an atrophic non-union animal model.2. Materials and methods
2.1. Preparation and characterization of porous
bioceramics
Hydroxyapatite (HAp) (CAPTALsS, Plasma Biotal Limited, US)
and β-TCP were used as the main raw materials in this study.
Reagent-grade N-isopropylacrylamide (NiPAAm), methacrylic
acid (MAA), the activator N,N,N’,N’-tetramethylethylenedia-
mine (TEMED), and the initiator ammonium persulfate (APS)
were purchased from Sigma-Aldrich, Inc. (US) and were used
without any further puriﬁcation. The other chemicals were of
analytical grade and were used without further puriﬁcation.
Poly[(N-isopropylacrylamide)-co-(methacrylic acid)] (p
(NiPAAm–MAA)) was synthesized by free-radical cross-link-
ing copolymerization in a solution of 99 mol% NiPAAm and
1 mol% MAA (PNM99:1); the main parameters were as
described previously (Tian et al., 2008). Brieﬂy, the target
amount of 5 g of NiPAAm and 40 μl of MAA were added to
25 mL of deionized water in a 100 mL reactor. The solution
was stirred for 1 h, deoxygenated by bubbling with nitrogen
for 40 min, and ﬁnally heated to 50 1C in a nitrogen environ-
ment. Then, 500 μl of TEMED and 0.05 g of APS were added to
the reactor to initiate polymerization. The reaction was
maintained at 50 1C under a nitrogen atmosphere for 24 h
with constant stirring. The p(NiPAAm–MAA)¼99:1 (PNM99:1)
hydrogel that formed was then puriﬁed by membrane dialysis
against distilled deionized water using a Spectra/Pros mem-
brane with a molecular weight cutoff (MWCO) of 1000. The
sample was then freeze-dried to form a white powder. The
puriﬁed copolymer was characterized as described. 1H –NMR
spectra were recorded on a nuclear magnetic resonance
spectrometer (Varian Gemini-200, US), and the sample was
dissolved in D2O. Molecular weights were determined using
ESI-MS on a quadrupole TOF mass spectrometer (Bruker
BioTOF Q, US). The LCST of the hydrogel was determined
using turbidity measurements. The turbidity of the polymer
solution was measured at 500 nm using a UV/VIS/NIR spec-
trometer (JASCO V570, Japan) equipped with a temperature
controller. Thermo-gelling was evaluated for the aqueous
30 wt% PNM99:1 hydrogel ﬁrst. The shrinkage ratio, [(D0–DS)/
D0]100%, is deﬁned as the ratio of the difference in
diameters between the original and shrunken hydrogel to
the original diameter of the hydrogel, where D0 is the
original diameter of the hydrogel, and DS is the diameter of
the hydrogel after shrinkage at each temperature. Thermo-
gravimetric analysis (TGA; Perkin–Elmer Pyris-Diamond ther-
mogravimetric analyzer, US) was used to examine the
thermal properties of the PNM99:1 sample and to determine
the sintering temperature. The TGA analysis was performed
using a 5 mg sample under a nitrogen gas atmosphere inplatinum crucibles. The scan rate was 10 1C/min from 25 to
800 1C.
The porous bioceramics were prepared using aqueous
solutions containing 2 ml of 0, 10, 15 and 20 wt% PNM99:1
hydrogel mixed with 2 g of HAp to form a ceramic slurry
using a planetary centrifugal mixer at 1000 rpm for 2 min
(Thinky Mixer AR-100, Thinky, Japan). The ceramic slurry was
then poured into an Al2O3 mold and dried to form a green
cylinder with a diameter of 6.070.1 mm and a height of
12.070.1 mm. The green cylinder was slowly heated (in a
Nabertherm HTC-03/14 electrical furnace (German) in an air
atmosphere) to 600 1C for 1.5 h, and the temperature was
then maintained at 600 1C for 30 min. Next, the temperature
was increased to 1200 1C over 30 min and kept at that
temperature for 30 min, followed by cooling to room tem-
perature. The porous chunk that was obtained was cut into
smaller pieces using a diamond saw to produce the desired
shapes. X-ray diffraction (XRD; Rigaku D/max VIII, Japan) with
CuKα radiation was used to characterize the phase composi-
tion of the bioceramics. Microstructure observations of the
bioceramic samples were performed using an optical camera
and scanning electron microscopy (SEM; Hitachi SU8000,
Japan). The bulk density of the complex geometric parts
and their various porosities were determined using the ASTM
procedure C373, which is based on Archimedes' principle. We
also recorded three-section images of each type of porous
bioceramic sample using a microscopic camera (MICROTECH
Mini Scope-V, M&T OPTICS CO., Taiwan). Subsequently, we
analyzed the pore size and area percentage using Feret's
diameter method in ImageJ software. Liquid permeability
experiments were performed using blue ink, which was
slowly added dropwise on the top surface of the columnar
porous bioceramics. Compressive strength tests were also
performed using the ASTM procedure C773-88, and the
compressive strength can be calculated using the following
formula: s¼F/A (F¼ load at fracture and A¼area of the disc
surface). The specimens used for compression testing were
usually cylinders with a height to diameter ratio of 2:1.
Specimens with a diameter of 5.770.2 mm and a height of
11.770.2 mm were loaded at a crosshead speed of 0.5 mm/
min (Instron 4400, Instron Corp., US). Six samples of each
group were used for a statistical analysis. All the porosity and
strength data were statistically analyzed and expressed as
the mean7standard deviation (SD).
2.2. Preparation of (rhBMP-2)-HAp-PLGA carriers
The rhBMP-2 carriers were microspheres (size range: 10 μm–
120 μm) synthesized using our previously described techni-
que (Wang et al., 2009), in which the main components are
poly (D,L-lactide-co-glycolide) (PLGA65/35; Sigma-Aldrich, US)
and hydroxyapatite (HAp; Alfa Aesars, A Johnson Matthey
Company, US). Brieﬂy, 250 μl of a PBS (phosphate-buffered
saline) buffer solution acted as the ﬁrst water-phase suspen-
sion. Then, 250 mg of the PLGA65/35 was dissolved in 2.5 ml
of dichloromethane to form a 10% PLGA oil-phase solution.
The ﬁrst water-phase solution and the 10% PLGA were mixed
at 1000 rpm for 15 min to form the ﬁrst water-in-oil (w/o)
microemulsion. The ﬁrst microemulsion (w/o) was added
to 10 ml of the 0.1% (w/v) polyvinyl alcohol (PVA) (PB-05,
j o u r n a l o f t h e m e c h a n i c a l b e h a v i o r o f b i o m e d i c a l m a t e r i a l s 2 7 ( 2 0 1 3 ) 6 4 – 7 6 67Chang Chun Petrochemical Co., Taiwan) second water-phase
solution and then stirred at 350 rpm for 4 h to form a second
microemulsion (W/O/W), eliminate the dichloromethane and
solidify the microspheres. These microspheres were collected
by centrifugation, washed with distilled water and lyophilized.
Finally, to effectively adjust the concentration of released
rhBMP-2, the surfaces of the 50mg lyophilized microspheres
were coated with a solution of 60 μl of PBS, 200 μg of rhBMP-2
(2000 ng, CHO-expressed; Catalog: 355-BM; R&D systems, US)
and 2 mg of HAp powder.
2.3. Cell viability of the porous bioceramic
In vitro tests were used for screening purposes, according to
ISO 10993–5. MC 3T3-E1 osteoblast-like cells were cultivated
in Dulbecco's modiﬁed Eagle's medium (DMEM) containing
10% fetal calf serum (FCS), 0.01% ascorbic acid, nonessential
amino acids and 100 U/ml penicillin/streptomycin (Gibco-
BRL; Grand Island, US) at 37 1C in a humidiﬁed incubator
containing 5 vol% CO2. The culture medium was replenished
every other day; for subculture, the cell monolayer was rinsed
with PBS and detached by incubation with trypsin-EDTA
(0.25 wt%) for 5 min at 37 1C. Changes in the cell viability of
the MC 3T3-E1 cells were quantitatively assessed with a
tetrazolium compound (MTS; Sigma, US) for 24 and 48 h
culture periods. In the presence of phenazine methosulfate
(PMS), this tetrazolium compound, 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tet-
razolium, inner salt (MTS), resulted in a water-soluble for-
mazan product that had an absorbance maximum at 550 nm
in PBS. The amount of colored product formed was propor-
tional to the number of cells and to the incubation time of the
cells with MTS/PMS. To indirectly evaluate the viability of
cells that contacted the material, 5000 cells per well were
seeded in a 96-well two-dimensional cell culture plate and
cultured at 37 1C in a humidiﬁed incubator containing 5 vol%
CO2. The dissolution extracts were prepared by adding the
culture medium to porous bioceramics (0.2 g/ml) that had
previously been incubated in DMEM at 37 1C for 24 h and
sterilized by 260 nm UV light. Conventional Al2O3 that had
also been incubated in DMEM at 37 1C for 24 h in the medium
(0.02 g/ml) at 37 1C for 24 h was used as a negative control.
Phenol diluents (0.3%) were used as a positive control and
were placed into each well (100 μl/well) and cultured at 37 1C
in a humidiﬁed incubator containing 5 vol% CO2. The culture
plates without samples were used as normal controls. After
24 and 48 h of cultivation, 10 μl of MTS solution (5 mg/ml in
PBS) was added to each well and incubated for another 4 h
(37 1C). The optical density (OD) of the water-soluble forma-
zan produced in the solution was measured using an ELISA
reader (SLT, Crailheim, Germany). The data were collected
and averaged from the ﬁve different wells per condition. The
data were plotted as the mean7standard deviation (SD)
(n¼3).
2.4. Experimental animals and surgical technique
All procedures were performed in accordance with the
speciﬁcations in the Guidelines for Animal Experiments of
Kaohsiung Medical University. Balb/C mice were anesthetizedby an intraperitoneal injection (3.2 mg/30 g body weight) of
ketamine (Ketalars, Parke-Davis, New Zealand) in combina-
tion with a 3.7 mg/30 g body weight dose of thiazine-
hydrochloride (Rompuns, Bayer HealthCare, Germany). In
the non-union animal model, we created a 1 mm gap with a
saw in the mid-part of the femur on the right side of a Balb/C
mouse. Before surgery, the porous bioceramic samples were
ﬁrst sterilized using dry heat at 80 1C for 24 h. In addition, the
rhBMP-2 carriers were produced using a sterile process, as far
as possible, and then sterilized using 260 nm UV overnight in
this study. A porous bioceramic spacer that was 2 mm in
diameter and 1 mm thick was placed in the gap, and both
ends of the bone were ﬁxed with a Π-shaped pin. (rhBMP-2)-
HAp-PLGA carriers (Wang et al., 2009) were placed beside the
bioceramic spacer, and the wound was closed with 4–0 silk
sutures. These mice were divided into four groups: the
control group, the rhBMP-2 carrier group, the bioceramic
spacer group and the bioceramic spacer with rhBMP-2 car-
riers groups. An empty bone defect without any scaffold was
regarded as the control group. For the rhBMP-2 carrier
surgical procedures, 5 mg of carrier (carrying approximately
200 ng of rhBMP-2) was compressed into one piece and then
placed either beside the porous bioceramic disc or into the
bone defect site alone for the rhBMP-2 group. Twelve mice in
each experimental group were utilized independently and
divided into two observation periods for the 6th and 8th
weeks after surgery (6 mice in each observation period).
2.4.1. Soft X-ray observation
At 0, 6 and 8 weeks after the operation, the femur fractures
were radiographically examined using soft X-rays (SOFTEX,
Model M-100, Japan) at 43 KVP and 2 mA for 1.5 s. The
appropriate magniﬁcation was applied throughout the obser-
vation period, and the resultant micrographs were compared
among all scaffolds and with the controls.
2.4.2. Histological analysis and immunostaining of bone
tissue
Histochemical and immunohistochemical analyses were con-
currently employed to assess the microscopic changes in the
bone tissue as a supplement to the X-ray observation. Prior to
hematoxylin-eosin (H&E) and immunohistochemical (IHC)
staining, all samples of bone tissue were decalciﬁed [0.5 M
EDTA-2H2O in DDW (186. 1 g/L)] for 2 weeks followed by
ﬁxation with 4% paraformaldehyde. The resultant samples
were embedded into parafﬁn wax, and 5 μm sections were
prepared. The sections were routinely stained with H&E and
observed using a microscope at 40 and 100 magniﬁca-
tion. Under 40 magniﬁcation, we deﬁned the counted callus
area as the area within 1 mm proximally and distally to both
fracture ends. The callus area around the graft was measured
using Image-Pro Plus 5.0 software (Media Cybernetics Inc.,
US). The percentage of bone matrix within the callus was
calculated and compared with that of the control group. IHC
staining of endothelial vessels for von Willebrand factor
(vWF) was performed as follows. The sections were treated
for 9 min with 0.15 mg/L of trypsin in phosphate buffer
at pH 7.8 and then incubated overnight at 4 1C with a 1:300
dilution of polyclonal rabbit antihuman vWF antibody (CHE-
MICON International, Inc., US). Goat anti-rabbit biotinylated
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1:300 dilution as the secondary antibody for 60 min at 37 1C.
An avidin–biotin–peroxidase complex (Vector Laboratories,
Burlingame, US) was applied at a 1:300 dilution for 60 min
at 37 1C. The peroxidase activity was detected using 0.4 mg/L
of 3,3′'-diaminobenzidine in phosphate buffer at pH 7.3 in the
presence of 0.12% H2O2. The sections were then counter-
stained with hematoxylin.
2.4.3. Statistical analysis
All the callus formation scoring data were statistically ana-
lyzed to express the mean7SD (n¼6). A one-way ANOVA was
performed, and the npo0.001 and nnpo0.0001 were compared
to the control or compared between treatment groups.3. Results and discussion
3.1. p(NiPAAm–MAA) copolymer synthesis
The 1H–NMR results, shown in Fig. 1(a) and (b), show the
NiPAAm monomer and PNM99:1 copolymer. The peak attrib-
uted to the methyl group in the NiPAAm monomer appeared
at 1.1 ppm, and the isopropyl CH signal was present at
3.9 ppm. In addition, the double-bond peaks of the NiPAAm
monomer were observed at 5.7 ppm and disappeared at
6.1 ppm. The structure of the PNM99:1 copolymer was also
supported by the 1H–NMR, as shown in Fig. 1(b). These data
contain two broad peaks (CHCH2) at 1.4 and 1.9 ppm, a
peak (CH3) due to the isopropyl group at 1.0 ppm, and a peak
(NHCH) at 3.8 ppm that was attributed to the hydrogen
proton of the pNiPAAm units of the chain. The minor MAA
units of the copolymer showed that the intensity of theFig. 1 – 1H NMR spectrum of NiPAAm monomer and
p(NiPAAm-co-MAA)¼99:1 (PNM99:1) copolymer.methyl group was signiﬁcantly enhanced due to the intro-
duction of the methyl group of pNiPAAm (chemical shift at
1.2 ppm) (Raﬁe et al., 2012). However, the double-bond peaks
of the NiPAAm monomer observed at 5.7 ppm and 6.1 ppm
disappeared. The FTIR result shown in Fig. S1 of the support-
ing information also indicated successful polymerization of
NiPAAm and MAA, as expected. The molecular weight of the
PNM99:1 copolymer as analyzed by LC-mass spectrometry
was approximately 1000 (mass spectrum (ESI): m/z 1060 (M)+)
(Fig. S2 of supporting information).
3.2. Temperature dependent thermo-gelling and
thermogravimetric analysis
Fig. S3 of the supporting information demonstrates that the
30% PNM99:1 hydrogel showed a transition at temperatures
between 32.5 1C and 34.1 1C. As the temperature increased
above 34.1 1C, a white dispersion was formed. Similar phase
transition temperatures (33.0 1C–35.0 1C) were also observed
for the 30% PNM97:3 (p(NiPAAm–MAA)¼97:3) hydrogel. As
the literature reports (Zhang et al., 2004), at temperatures
below the LCST, pNiPAAm hydrogels show water-swollen
properties due to the hydrogen bond interactions between
water and the hydrophilic amide groups of the polymer. At
temperatures near or higher than the LCST, hydrophobic
interactions between the isopropyl pendant groups increase,
and the hydrogels appear to be hydrophobic; the pNiPAAm
starts to aggregate, and phase separation occurs. In addition,
Feil et al. reported (Feil et al., 1993) that the presence of
hydrophilic moieties in polymer networks containing
NiPAAm caused an increase in the LCST value in comparison
with the value found with pNiPAAm. Therefore, the phase
transition temperature increased as the MAA content
increased. This change is because the increased hydrophili-
city of the copolymer resulted in an increase in the phase
transition temperature.
The key point is that reverse thermo-responsive hydrogels
containing pNiPAAm and p(NiPAAm–MAA) can decrease their
volume when the temperature is increased. Fig. 2 shows
photographs of aqueous 30 wt% PNM99:1 hydrogels taken at
different temperatures and stages of shrinkage. The diameter
size ratio of the 30% PNM99:1 hydrogel decreased from 100%
to 25% when the temperature increased from 25 1C to 300 1C.
This hydrogel ratio decreased by nearly 75% as the tempera-
ture gradually increased to 300 1C, which indicates that the
shrinking volume size of the PNM99:1 induced compression
of all the components in response to high temperature. This
phenomenon can be regarded as functioning in a manner
similar to the cold isostatic press (CIP) step before the powder
sintering densiﬁcation process. In other words, the reverse
thermo-responsive hydrogel can evenly mix with HAp pow-
der, and the volume of this hydrogel mixture will shrink and
compress the HAp powder as the sintering temperature
increases. Finally, sintering densiﬁcation is expected via free
volume contraction, which will increase the mechanical
properties after the formation of the porous bioceramics.
TGA was used for the thermal analysis of the polymers to
determine the burn-out temperature during the sintering
process. Fig. S4 of the supporting information shows the
thermograms of the PNM99:1 polymer in the temperature
(25 °C) (50 °C) (150 °C) (250 °C) 
Fig. 2 – The change of PNM99:1 hydrogel in the appearance, as shown in optical microphotographs (a), and shrinkage ratio of
PNM99:1 hydrogel in diameter (b).
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burn-out temperature of PNM99:1 is clearly located at 600 1C.
Therefore, the slurry mixture of PNM99:1 polymer and HAp
powder was slowly heated to 600 1C over 1.5 h and main-
tained at 600 1C for 30 min to result in shrinkage and then
burn-out.
3.3. Characterization of the porous bioceramic
Fig. 3(a) shows the porous bioceramic samples of various
concentrations of PNM99:1 hydrogel after 1200 1C sintering.
These PNM99:1 hydrogels can act as a binder template for
preparing a high integrity porous bioceramic (ϕ: 5.770.2 mm/
height: 11.770.2 mm); i.e., they do not have cracks or easily
released particles. The morphology of different concentra-
tions of the PNM99:1 hydrogel and HAp slurry on porous
bodies after 1200 1C sintering is shown in Fig. 3(b–f) using SEM
images. The macropore structure and distribution are also
shown. These macropores can be greater than 300–500 μm,
and smaller pore sizes of 100–300 μm are also present. Those
macropores (100–500 μm) should also come from the air
bubbles generated during the mixing process because air
bubbles are known to be entrapped when viscous ﬂuids are
stirred using mechanical force; the plastic viscosity decreased
with increasing air content (Rust and Manga, 2002). From the
results of the pore size and pore area percentage analysis
(Fig. S5 of the supporting information) showed the bioceramic
product that was fabricated without PNM99:1 hydrogel was
unlikely to cause pores larger than 100 μm. In contrast, a
range of pore sizes was easy to obtain for the porous
bioceramics that were fabricated from 10–20% PNM99:1
hydrogel solutions. For example, three intervals of pore areas
(100–300 μm, 300–500 μm and 500–700 μm) accounted for
approximately 34–42%, 22–28% and 21–23%, respectively, of
the overall pore area from the 100–1000 μm pore range (Fig. S5
(e)). An optimal pore size exists for successful cell inﬁltrationand bone tissue ingrowth: 100–350 μm for bone tissues
(Komlev and Barinov, 2002). Moreover, reports (Hulbert
et al., 1970; Stevens, 2008; Uchida et al., 1985) indicated that
pores of sizes between 100 and 1000 μm play an important
role in cellular and bone ingrowth, being necessary for blood
ﬂow distribution. This ﬁnding indicated that the porous
bioceramic products that were fabricated using this new
method have a suitable pore size range (100–1000 μm) for
the growth of bone and blood vessels.
The magniﬁed morphologies of porous bodies with differ-
ent concentrations of the PNM99:1 hydrogel slurry after
1200 1C sintering are also shown in Fig. 4(a–e) using SEM
images. We supposed that these crevices formed due to
residual space in the PNM99:1 polymer after burn-out at high
temperatures. In addition, the minimum crevices (o5–
100 μm) should be attributed to a lack of sintering densiﬁca-
tion. A characteristic of similar methods is the potential for a
wide variation in porosity and pore size by using different
templates, which act as porogens within the ceramic (Dong
et al., 2001; Tadic et al., 2004; Tampieri et al., 2001). However,
calcination is often required to remove these organic tem-
plates. The grain sizes are on the order of a micrometer, and
most of the individual granular HAp particles are sintered
and coalesced. The current methods to introduce porosity
into a bioceramic are mainly based on the admixture of a
combustible reverse thermo-responsive hydrogel that burns
away during sintering and on the air bubbles generated
during the mixing process that leave free spaces in the
resulting object. However, macropore formation from poly-
mer porogens and induced air bubbles in the slurry method
usually lead to closed pores that are connected by small-
diameter connecting channels only, i.e., not to an obvious
interconnecting, bone-like pore network. Liquid permeability
tests were performed to understand whether these crevices
have liquid permeability and whether those large pores have
interconnection channels. The liquid permeability results of
Fig. 3 – Optical photograph (a) and SEM micrographs (50; b–f) of whole block of porous HAp/β-TCP (6/4) bioceramics with
different concentrations of PNM99:1 hydrogel.
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body of a porous bioceramic because the 80 μl of blue ink was
slowly added dropwise to the top surface of a columnar
porous bioceramic. Therefore, a porous bioceramic fabricated
using this type of new method will allow the movement of
nutrients or metabolites when implanted in animals. Further-
more, an alternative route is to create different ratios of
biphasic bioceramics from HAp and β-TCP, and then the more
highly soluble β-TCP can be dissolved to help produce
interconnecting pores.
Fig. 5 shows the dependence of porosity and compressive
strength on the four concentrations of PNM99:1 hydrogel.
The calculations were performed within the range of 0 wt%,
10 wt%, 15 wt% and 20 wt% PNM99:1 hydrogel. When the con-
centration of PNM99:1 hydrogel was increased, the porosityalso increased by 47.6%, 66.2%, 68.4% and 65.2%, respectively,
but the porosity of the 15 wt% PNM99:1 was even greater than
that of the 20 wt% PNM99:1. The difference may result from
the coordination of three factors, air bubbles, PNM99:1 poly-
mer residual space, and sintering densiﬁcation via free
volume contraction, because the relative density plays an
important role in determining the mechanical properties of
porous ceramics. The advantage of high-porosity scaffolds for
achieving a good cellular distribution has been reported, and
it is critical to select the correct pore size (Solchaga et al.,
1999). However, few methods can completely satisfy all the
necessary porous bioceramic requirements, namely, a con-
trolled level of high porosity combined with good mechanical
properties. Thus, porosity can adversely affect the important
mechanical characteristics of a scaffold. Therefore, the
Fig. 4 – SEM micrographs (3000; a–d) of whole block of porous HAp/β-TCP (6/4) bioceramics with different concentrations of
PNM99:1 hydrogel.
Fig. 5 – Porosity and compressive strength of the porous
HAp/β-TCP (6/4) bioceramics after 1200 1C sintered.
Fig. 6 – XRD patterns of the porous HAp/β-TCP (6/4)
bioceramics after 1200 1C sintered, commercial HAp and
β-TCP. (β¼β-TCP, H¼HAp).
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compressive strength of cancellous bone, which has been
reported to be in the range 4–12 MPa (Gauthier et al., 1999;
Huglin et al., 1997; Ramay and Zhang, 2003). The compressive
strength of these porous bioceramics was examined at
8.7 MPa, 6.8 MPa, 4.1 MPa and 3.5 MPa for the range of
0 wt%, 10 wt%, 15 wt% and 20 wt% PNM99:1 hydrogel, respec-
tively (Fig. 5). Han et al. reported that the porosity and grain
contacting area are two key factors affecting the strength of
ceramic foams (Han et al., 2002). The phenomenon of the
compression strength being higher at a porosity of 15 wt%
PNM99:1 than at a porosity of 20 wt% PNM99:1 should result
from the grain contacting area. Of course, the mechanicalstability should decrease for increased porosity. However,
there the compressive strength does not signiﬁcantly
increase with increasing relative density in this case. Thus,
the reverse thermo-responsive hydrogel can be regarded as
acting like a cold isostatic press (CIP) before the powder
sintering processing to shrink and compress the HAp powder,
Table 1 – Phase analysis of porous bioceramics by XRD spectrum.
Naming HAp+β-TCP raw
materials (g)
β-TCP raw
materials (wt%)
P99N1Mn
(wt%) (1 ml)
HAp/β-TCP phase ratio
before 1200 1C sintereda (%)
HAp/β-TCP phase ratio
after 1200 1C sintereda (%)
HAp/β-TCP (7/3) 2.0 0 15 100 65
HAp/β-TCP (6/4) 2.0 20 15 79 59
HAp/β-TCP (4/6) 2.0 30 15 66 41
HAp/β-TCP (3/7) 2.0 40 15 62 29
n P99N1M is p(NiPAAm–MAA)¼99:1.
a The phase ratio (% ) refers to the HAp/β-TCP phase ratio of the peak areas by XRD compared with actual weight ratio.
Fig. 7 – MTS assay of 3T3-E1 osteoblast-like cells was
evaluated on different extract solutions of various samples
for 24 and 48 h. Data are presented as the mean7SD (n¼3).
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iation in compressive stress using this novel reverse thermo-
responsive hydrogel method is due to the porosity, pore
distribution and densiﬁcation of the ceramic skeleton.
Fig. 6 shows the XRD patterns of the slurry after sintering
at 1200 1C. The XRD peaks of all of the diffraction patterns
agree well with those of standard HAp and β-TCP in the
powder diffraction ﬁle (Card no. 9-432 and 9-169). A phase
calibration curve of the XRD spectrum was prepared using
standard HAp and β-TCP, and different HAp/β-TCP phase
weight ratios can be found in Table 1. Table 1 shows the
HAp/β-TCP phase weight ratio of porous bioceramics at 65/35,
59/41, 41/59 and 29/71 following different initial HAp/β-TCP
ratios of raw materials for the range of 0 wt% β-TCP, 21 wt%
β-TCP, 34 wt% β-TCP and 59 wt% β-TCP, respectively. High-
temperature treatment will lead to phase decomposition that
results in a different ratio of β-TCP/HAp and a highly crystal-
line, sintered porous bioceramic with a different rate of
biodegradation (Park et al., 2009). However, the HAp/β-TCP
ratio of 6/4 is commonly used in clinical applications; thus, an
animal product was obtained for this study.
3.4. Cell viability of porous bioceramics
Fig. 7 shows the results of an indirect cytotoxicity test for the
control groups against the porous bioceramic after incubation
for 24 and 48 h. There were no statistically signiﬁcant differ-
ences between the normal control, the negative control of
Al2O3 and the bioceramic. Conversely, the viability of the
phenol diluent positive control showed a tendency towards a
severe decline after 24 and 48 h. These results indicated that
our fabrication process could completely remove the PNM99:1
polymer and resulted in no cell toxicity effects for the pure
porous calcium phosphate bioceramics. It is generally
accepted that the in vitro cell-material interaction is a useful
criterion in the evaluation of newly synthesized biomaterials.
3.5. In vivo experiments
3.5.1. Soft X-ray observation
Gross examination of the callus formation was performed
using the X-ray photographs. Fig. 8(a1, b1) and (a2, b2) show
X-ray images of the control group and the rhBMP-2 carrier
group, respectively. All defects of both groups (a1, b1, a2, b2)
had some scattered bridging callus formation between 6
weeks and 8 weeks, but there were still obvious gaps (white
arrows) in the control group at the 6th week and 8th weeks.
In contrast, the X-ray images of the 1-mm defect in thefemurs of the bioceramic spacer group and the bioceramic
spacer with rhBMP-2 carriers group in Fig. 8(a3, b3) and (a4,
b4) still showed an in situ bioceramic spacer at the 6th and
8th weeks, which was not present in the non-treated control.
None of the X-ray micrographs of the samples after 6 weeks
and 8 weeks showed good union, including those from the
bioceramic spacer with rhBMP-2 carriers group. We supposed
that the bioceramic scaffold was not absorbed completely
within this short time period, and it was hard to differentiate
the bone matrix within the scaffold. Therefore, histological
images were needed to analyze the difference.
3.5.2. Histological analysis and bone tissue callus area
calculation
In Fig. 8(a1) and (b1), a histological analysis of the control
group was performed at the 6th and 8th weeks. We designed
an atrophic non-union model in our control group. In this
model, both bone ends were shrunken, and the ﬁbrous tissue
ﬁlled the defect. Additionally, the ﬁssure joint between the
ﬁbrous tissue formed a pseudoarthrosis in Fig. 8(b1) (most
severe form of arrest in fracture repair) according to the
classiﬁcation system reported by Allen et al. (Allen et al.,
1980). In contrast, histological micrographs of the 1-mm
defect in the femurs of the rhBMP-2 carrier group, bioceramic
spacer group and bioceramic spacer with rhBMP-2 carriers
groups in Fig. 8(a2, b2), (a3, b3) and (a4, b4), respectively,
showed better callus formation both around the defect site
and wrapping the bioceramic scaffold. At the 8th week
Fig. 8 – Radiography and histological study of one millimeter non-union Balb/C mouse model at 6 and 8 weeks after
implantation of rhBMP-2 carriers only, HAp/β-TCP (6/4) bioceramic spacer and HAp/β-TCP (6/4) bioceramic spacer with rhBMP-
2 carriers. (a1, b1: control group), (a2, b2: rhBMP-2 carriers group), (a3, b3: bioceramic spacer group) and (a4, b4: bioceramic
spacer with rhBMP-2 carriers).
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with rhBMP-2 carriers group had more calluses bridging
the defect area around the scaffold than did the rhBMP-2
carriers group. We further used Image-Pro Plus to quantify
the calciﬁed callus in the H&E-stained histological sections
matrix. The results showed that the percentages of bone
callus formation in the rhBMP-2 carriers group, the biocera-
mic spacer group and the bioceramic spacer with rhBMP-2
carriers group were signiﬁcantly better than those of the
control group at 6 weeks and 8 weeks (Fig. 9). In addition, the
results from the bioceramic spacer with rhBMP-2 carriers
group were also signiﬁcantly better than those of the rhBMP-2
carriers group at 8 weeks. The rhBMP-2 controlled-release
proﬁle results of our previous study showed an effective dose
of greater than 20 ng/ml of constant rhBMP-2 release,
which induced signiﬁcant bone formation during the ﬁrst
one-week period in a bone graft model (Wang et al., 2009).
However, that dose was unable to effectively treat atrophicnonunion bone defects because of the lack of a scaffold that
could provide an osteoconductive effect. Therefore, we sup-
posed that the porous bioceramic of our samples could
provide a good osteoconductive surface on which bone
formation can occur. Moreover, quantiﬁcation at 8 weeks
indicates that the bioceramic spacer with rhBMP-2 carriers
worked better than the bioceramic spacer after. We supposed
that the dual effects of the bone growth factors of the
osteoconductive bioceramic and the osteoinductive rhBMP-2
carriers should have better bone formation than other
groups.
3.5.3. Immunostaining of bone tissue
After 6 weeks of treatment, the formation and growth of new
blood vessels were obviously displayed, as observed using
vWF staining of the endothelial tissue in the bioceramic
spacer and the bioceramic spacer with rhBMP-2 carriers
groups. Fig. 10 shows that the bioceramic spacer and
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scattered brown-colored epithelium tissues in the defect area
than did the control group at 6 and 8 weeks. TheFig. 9 – Histological quantiﬁcation study of one millimeter
non-union Balb/C mouse model at 6 and 8 weeks after
implantation of rhBMP-2 carriers only, HAp/β-TCP (6/4)
bioceramic spacer and HAp/β-TCP (6/4) bioceramic spacer
with rhBMP-2 carriers by calculated the cell ingrowth into
transplant bone. Data are presented as the mean7SD (n¼6).
(Control: without any treatment, 2H2B: rhBMP-2 carriers
group, BC: bioceramic spacer group, and 2H2B/BC:
bioceramic spacer with rhBMP-2 carriers) (npo0.001 and
nnpo0.0001 was compared to the control or compared
between treatment groups.).
Fig. 10 – Immunohistochemistry study of one millimeter non-unio
HAp/β-TCP (6/4) bioceramic spacer and HAp/β-TCP (6/4) bioceramic sp
sites of blood vessels. (a1, b1(400 ): control group), (a2, b2: biocera
carriers). (For interpretation of the references to color in this ﬁgureneovascularization represents the new vessel ingrowth, and
this process can bring more bone marrow stromal cells to
facilitate bone formation.
In our animal study, the callus formation around the
bioceramic spacer and around the bioceramic spacer with
rhBMP-2 carriers was signiﬁcantly more than that of the
control group at 6 weeks after implantation (Fig. 8). The
histological results also showed that signiﬁcant neovascular-
ization was found in both the bioceramic spacer group and
bioceramic spacer with rhBMP-2 carriers group 6 and 8 weeks
after grafting, while that result was rarely observed in the
control group (Fig. 10). The rhBMP-2 carrier group exhibited
angiogenesis but was not better than the bioceramic spacer
with rhBMP-2 carriers group. These results indicated that the
osteoconductive effect of the HAp/β-TCP bioceramic spacer
and the released effective osteoinductive dose of rhBMP-2
signiﬁcantly stimulated new vessels that invaded around and
into the ceramic scaffold cavities, which might help transport
stem cells into the scaffold to facilitate bone regeneration. In
the rhBMP-2 group, however, the large defect had no niche
surface for new vessels to creep over even when stimulated
by rhBMP-2. Consequently, the bone marrow stromal cells
could not be transported to the defect area, which reasonably
explains the fact that the rhBMP-2 group cannot work as well
as in our previous study (Wang et al., 2009).4. Conclusions
This study shows the successful synthesis of the reverse thermo-
responsive copolymer of p(NiPAAm–MAA) by polymerization ofn Balb/C mouse model at 6 and 8 weeks after implantation of
acer with rhBMP-2 carriers and red arrows identify the incipient
mic spacer group) and (a3, b3: bioceramic spacer with rhBMP-2
legend, the reader is referred to the web version of this article.)
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reverse thermo-responsive hydrogel, which can shrink as the
temperature increases, the compression function can be
regarded as a cold isostatic pressing (CIP) effect to help densiﬁca-
tion of the ceramic during sintering. Few techniques for produ-
cing highly porous bioceramics with similar cancellous bone
compression strength (4∼5MPa) have been developed. The
novel methods to introduce porosity into a bioceramic
are mainly based on the admixture of a combustible reverse
thermo-responsive hydrogel that burns away during sintering
and on the air bubbles generated during the mixing process that
leave free spaces in the resulting object. The optimal compres-
sive strength and porosity of the porous bioceramics were
examined between 6.8 and 4.1 MPa and 66.2% and 68.4% under
10–15 wt% PNM99:1 conditions. In addition, the HAp/β-TCP ratio
of biphasic bioceramics can be adjusted to 7/3, 6/4, 4/6 and 3/7
during the 1200 1C sintering process. In animal studies, the
results showed that none of the X-ray micrographs of the
samples after 6 weeks and 8 weeks indicated good union,
including those of the bioceramic spacer with rhBMP-2 carriers
group. Histological micrographs of the 1-mm defect in femurs
with the rhBMP-2 carrier group, the bioceramic spacer group and
the bioceramic spacer with rhBMP-2 carriers group, however,
appeared to have had better callus formation around the femur
defect site. In the rhBMP-2 carriers only group, large bone defects
were still unable to be effectively treated without any scaffold.
The porous bioceramic scaffold possessed better osteoconductive
ability than the rhBMP-2 carriers only group. The dual effects of
bone growth factors from osteoconductive bioceramic and
osteoinductive rhBMP-2 carriers can have better bone formation
than other groups in addition to better callus formation and
signiﬁcant neovascularization. The use of porous bioceramic
scaffolds with controlled release rhBMP-2 carriers to support
bone growth shows a wealth of potential clinical applications for
the treatment of non-union fractures.Acknowledgments
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